Webinar Overview: Comparing Leukopaks and iPSCs for Cell Therapy Development
Are you interested in cellular starting material for research and therapeutic development? While leukopaks and induced pluripotent stem cells (iPSCs) are both viable options, it's not always clear which is better suited for your specific needs.
This question is particularly relevant in today’s cell and gene therapy industry. Knowing how to optimize the cellular starting material for your purpose is going to mitigate risk and significantly shorten the timeframe for the development of effective therapeutics.
In this webinar, our experts tackle this important question by comparing these two different cellular starting material sources and providing impactful data to help you make an informed decision.
You will learn:
- Donor selection strategies to reduce variability in leukopaks
- Why iPSCs can be the next-generation cellular starting material
- Effective strategies to safeguard against risks associated with using iPSCs
- How iPSCs can be successfully used as starting materials for NK cell-based therapies
Webinar Presenters
Raluca Dumitru, MD, PhD
Scientific Sales Director - Cell Solutions
Charles River
Benjamin Fryer, PhD
Chief Executive Officer
Pluristyx